A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

Trial Details

NCT ID
NCT06476808
Phase
PHASE1
Sponsor
Bristol-Myers Squibb
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BMS-986463
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  • Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be ob…
  • Participants must have an unresectable/metastatic carcinoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →